Showing 1421-1430 of 2656 results for "".
- Bayer Strikes Alliance to Advance CureVac’s COVID-19 Vaccine CVnCoVhttps://modernod.com/news/bayer-strikes-alliance-to-advance-curevacs-covid-19-vaccine-cvncov/2478735/Bayer said that it has reached an agreement to further the development, supply and key territory operations of CureVac’s COVID-19 vaccine candidate CVnCoV. The companies indicated that they plan to combine their strengths for CureVac to be in a position to supply “hundreds of millions
- Moderna’s COVID-19 Vaccine Becomes Second to Nab EU Authorizationhttps://modernod.com/news/modernas-covid-19-vaccine-becomes-second-to-nab-eu-authorization/2478725/The European Commission on Wednesday granted a conditional marketing authorization for Moderna’s COVID‑19 vaccine mRNA-1273, making it the second coronavirus vaccine authorized in the EU. The decision comes hours after the European Medicines Agency (EMA) had recommended authorizing mRNA-127
- EU Authorizes First COVID-19 Vaccine With Pfizer, BioNTech’s Comirnatyhttps://modernod.com/news/eu-authorizes-first-covid-19-vaccine-with-pfizer-biontechs-comirnaty/2478691/The European Commission on Monday granted a conditional marketing authorization to Pfizer and BioNTech’s coronavirus vaccine BNT162b2, which will go by the name Comirnaty, with the decision coming mere hours after the Committee for Medicinal Products for Human Use (CHMP) gave its backing fo
- FDA Panel Endorses Moderna’s COVID-19 Vaccine for Emergency Usehttps://modernod.com/news/fda-panel-endorses-modernas-covid-19-vaccine-for-emergency-use/2478678/An FDA advisory panel on Thursday voted 20-0, with one abstention, that the benefits of Moderna’s COVID-19 vaccine mRNA-1273 outweigh its risks in people 18 years and older. The panel backing sets the stage for the FDA to issue an emergency-use authorization (EUA) for the candidate, which i
- Most Doses of Lilly, Regeneron’s COVID-19 Antibody Treatments Are Going Unusedhttps://modernod.com/news/most-doses-of-lilly-regenerons-covid-19-antibody-treatments-are-going-unused/2478665/Moncef Slaoui, chief scientific advisor to the US government’s Operation Warp Speed program, estimates that only 5% to 20% of the roughly 65,000 doses of COVID-19 antibody treatments shipped to states around the country every week end up going to patients. He suggested this was disappointin
- FDA Review Confirms Efficacy of Moderna’s mRNA-1273 Vaccine Against COVID-19https://modernod.com/news/fda-review-confirms-efficacy-of-modernas-mrna-1273-vaccine-against-covid-19/2478666/According to briefing documents released ahead of an FDA advisory panel meeting on December 17, agency staff concluded that the efficacy of Moderna’s candidate COVID-19 vaccine mRNA-1273 at preventing coronavirus infections 14 days after a second dose was consistent, at 94.1%, with results
- US Government to Buy 100 Million More Doses of Moderna’s COVID-19 Vaccinehttps://modernod.com/news/us-government-to-buy-100-million-more-doses-of-modernas-covid-19-vaccine/2478657/Moderna announced that the US government has exercised its option to purchase an additional 100 million doses of the drugmaker’s COVID-19 vaccine candidate mRNA-1273, bringing its confirmed order commitment to 200 million doses in the US. CEO Stéphane Bancel remarked that “we c
- UK Government Asks Regulator to Clear “Temporary Supply” of AstraZeneca’s COVID-19 Vaccinehttps://modernod.com/news/uk-government-asks-regulator-to-clear-temporary-supply-of-astrazenecas-covid-19-vaccine/2478594/The UK government on Friday said that it formally asked the Medicines and Healthcare products Regulatory Agency (MHRA) to assess the suitability of AstraZeneca’s COVID-19 vaccine candidate AZD1222 for “temporary supply.” Health and Social Care Secretary Matt Hancock noted that t
- FDA Authorizes Regeneron’s Dual COVID-19 Antibody Treatment for Emergency Usehttps://modernod.com/news/fda-authorizes-regenerons-dual-covid-19-antibody-treatment-for-emergency-use/2478587/The FDA has issued an emergency-use authorization (EUA) to Regeneron’s filing for casirivimab and imdevimab to be administered together to treat mild-to-moderate COVID-19 in adults and paediatric patients. The monoclonal antibodies, also referred to as REGN-COV2 or as REGEN-COV2 when used i
- Early Phase 3 Data Show Pfizer, BioNTech’s COVID-19 Vaccine Over 90% Effectivehttps://modernod.com/news/early-phase-3-data-show-pfizer-biontechs-covid-19-vaccine-over-90-effective/2478507/Results from the first interim analysis of a phase 3 study of Pfizer and BioNTech’s BNT162b2 showed that the experimental mRNA-based vaccine candidate was more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced M